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Noteworthy heterogeneity exists in the rare diseases associated with childhood glaucoma. Primary congenital glaucoma is mostly
sporadic; however, 10% to 40% of cases are familial. CYP1B1 gene mutations seem to account for 87% of familial cases and 27% of
sporadic cases. Childhood glaucoma is classified in primary and secondary congenital glaucoma, further divided as glaucoma
arising in dysgenesis associated with neural crest anomalies, phakomatoses, metabolic disorders, mitotic diseases, congenital
disorders, and acquired conditions. Neural crest alterations lead to thewide spectrumof iridocorneal trabeculodysgenesis. Systemic
diseases associated with childhood glaucoma include the heterogenous group of phakomatoses where glaucoma is frequently
encountered in the Sturge-Weber syndrome and its variants, in phakomatosis pigmentovascularis associated with oculodermal
melanocytosis, and more rarely in neurofibromatosis type 1. Childhood glaucoma is also described in systemic disorders of
mitotic and metabolic activity. Acquired secondary glaucoma has been associated with uveitis, trauma, drugs, and neoplastic
diseases. A database research revealed reports of childhood glaucoma in rare diseases, which do not include glaucoma in their
manifestation. These are otopalatodigital syndrome, complete androgen insensitivity, pseudotrisomy 13, Brachmann-de Lange
syndrome, acrofrontofacionasal dysostosis, caudal regression syndrome, and Wolf-Hirschhorn syndrome.
1. Introduction
Childhood glaucoma is a rare disorder that occurs from
birth until teenage years. It usually results in grave visual
deterioration [1]. In the pediatric population approximately
8% of blindness has been attributed to the condition [2].
The European Glaucoma Society discriminates primary
congenital glaucoma (birth to 2 years of age) and early juvenile
glaucoma (2 years of age to puberty), due to incomplete devel-
opment of trabecular meshwork, from secondary childhood
glaucoma [3].
Secondary childhood glaucoma is defined as associ-
ated with congenital ocular anomalies such as conditions
associated with mesodermal dysgenesis of the neural crest,
phakomatoses characterized by hamartomas, metabolic dis-
orders, mitotic disorders, and other congenital disorders and
associated with acquired conditions such as tumors, uveitis,
and trauma [3]. Finally, there are rare case reports of diseases
that do not normally present glaucoma in their manifestation
where the heterogeneity and sporadic nature of the cases
make correlations with systemic syndromes and diseases
complex and difficult. The purpose of this paper is to review
the major conditions associated with secondary childhood
glaucoma, providing epidemiological data and notions on
pathophysiogenesis, and to assess rare diseases that usually do
not include congenital glaucoma among theirmanifestations.
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Table 1: Classification of childhood glaucoma.
Primary congenital glaucoma (trabeculodysgenesis)
Secondary childhood glaucoma
Mesodermal dysgeneses of neural crest
Iridocorneal trabeculodysgenesis
(i) Aniridia
(ii) Axenfeld-Rieger’s anomaly (syndrome if systemic associations)
(iii) Peter’s anomaly (syndrome if systemic associations)
(iv) Marfan’s syndrome
(v) Weill-Marchesani’s syndrome
Von Recklinghausen’s syndrome
Phakomatoses Encephalotrigeminal angiomatosis (Sturge-Weber syndrome and variants such asKlippel-Trenaunay syndrome)
Oculodermal melanocytosis
Lowe’s syndrome
Metabolic disorders Homocystinuria
Mucopolysaccharidoses
Mitotic disorders Juvenile xanthogranuloma
Trisomy 13 (Patau’s syndrome)
Persistent hyperplastic primary vitreous
Other congenital disorders
Congenital cataract:
(i) In phakic eyes
(ii) In aphakic eyes after early surgery
Rubinstein-Taybi syndrome
Congenital rubella
Uveitis
Trauma (hyphema, angle recession, and ectopia lentis)
Glaucoma associated with acquired conditions Steroid or drug induced
Tumors (benign/malignant, ocular/orbital)
Retinopathy of prematurity
2. Epidemiology
2.1. Primary Congenital Glaucoma. The incidence of child-
hood glaucoma is 1 in 10,000 to 68,000 live births. A new
case of primary congenital glaucoma is diagnosed about once
every 5 years in a general ophthalmology center in North
America or Western Europe [4–6]. The highest prevalence
of childhood glaucoma has been recorded in the Middle
East (1 : 2500) [7] and in Slovakia (1 : 1250) [8]. In previous
epidemiological studies, the incidence of primary congenital
glaucoma was reported as 1 in 10,0003 [9, 10] to 1 in 12,5005
in Western countries. A recent study reported the incidence
as 3.31 in 100,000 (1/30,200) in Great Britain and 5.41 in
100,000 (1/18,500) in the Republic of Ireland [5]. Recently,
the incidence of primary congenital glaucoma in Spain was
reported as 2.85 per 100,000 (1 in 38,000). This is comparable
to results in an Australian study where the incidence was 1 in
30,000 births [11]. The presence of consanguinity of parents
can increase the incidence by 5 to 10 times [3]. In about 70%of
cases, patients’ both eyes are affected and it is more common
among males [3].
Large epidemiological studies are difficult to carry out
as childhood glaucoma presents so infrequently, even if it
is the most common glaucoma in the pediatric population
[12]. Moreover, since childhood glaucoma appears in the
context of systemic diseases, most reports do not specifically
describe ophthalmologic anomalies. Therefore, evaluation of
the relationship between childhood glaucoma and rare dis-
eases becomes difficult. Table 1 is a classification of childhood
congenital glaucoma.
2.2. Mesodermal Dysgeneses of the Neural Crest. The first
group of rare systemic diseases leading to secondary child-
hood glaucoma are those associated with mesodermal dys-
genesis of the neural crest [13]. The Axenfeld-Rieger syn-
drome prevalence is 1–9/1000 000 [14] and glaucoma has
been observed in 50% of patients [13]. The prevalence of
Peter’s syndrome is beneath 1/1000000 [14]. Aniridia has an
estimated prevalence between 1 : 40,000 and 1 : 100,000 [15]
and the incidence of glaucoma in congenital forms ranges
from 6% to 75% [16–18]. Marfan syndrome is a connective
tissue disorder with autosomal dominant inheritance and a
prevalence of 1 : 5000 [19]. In an international study including
1,000 patients with this syndrome, more than half presented
eye manifestations such as myopia (53%), ectopia lentis
(54%), and glaucoma (2%) [20]. Weill-Marchesani syndrome
is a very rare systemic disease that implicates anomalies of
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connective tissue [21] and its prevalence has been estimated
at 1 : 100,000 [22]. The main ocular anomalies of Weill-
Marchesani syndrome are microspherophakia, ectopia lentis,
glaucoma, and myopia. Microspherophakia occurs in 84%
of cases, ectopia lentis in 73%, and glaucoma in 80%; severe
myopia and cataract are also reported [21].
2.3. Phakomatoses. The second group of rare diseases linked
with secondary childhood glaucoma are the phakomatoses
characterized by hamartomas. Von Recklinghausen’s diseases
or neurofibromatosis type 1 is characterized by autosomic
dominant inheritance and an incidence of about 1 in 3000
[23]. Glaucoma has been reported in 1/300 patients with this
condition [24]. However, a study on 95 patients, with neurofi-
bromatosis type 1, revealed that 23% of 56 patients presented
orbitofacial involvement and had ipsilateral glaucoma [25].
Sturge-Weber syndromehas a frequency of approximately
1 in 50,000 births [26]. Glaucoma affects 50% to 70%
of patients with this syndrome and its variants (such as
Klippel-Trenaunay syndrome) and can be early- or late-onset
depending on the age of manifestation [27]. In about 60%
of cases the cause is due to anterior chamber abnormalities
while in approximately 40% of cases the cause is raised
episcleral venous pressure [28]. Oculodermal melanocytosis
is a rare condition more frequently encountered in the
Asian population with a prevalence of 0.014%–0.034% [29].
Glaucoma is found in about 10% of patients and the patho-
genesis may be congenital, developmental or associated with
the diffuse characteristic oculodermal hyperpigmentation of
the disease which leads to melanocytic glaucoma [30–32].
Phakomatosis pigmentovascularis is a rare combination of
oculodermal melanocytosis and Sturge-Weber syndrome (or
Klippel-Trenaunay syndrome). In a review of the literature
on 281 Asian patients with oculodermal melanocytosis, 9
patients had phakomatosis pigmentovascularis and glaucoma
was present in all cases [30].
2.4. Metabolic Disorders. The metabolic disorders leading to
childhood glaucoma include mucopolysaccharidoses, Lowe’s
syndrome, and classical homocystinuria. Lowe’s syndrome
(oculocerebrorenal syndrome) has a prevalence of 1 in
500,000 [33]. Several cases of secondary congenital glaucoma
associated with this disease have been reported; Walton et al.
reviewed 7 patients and found that 71% of patients had glau-
coma [34]. Classical homocystinuria is caused by cystathio-
nine b-synthase (CbS) deficiency [35–37]. The detection rate
of CbS deficiency is 1 in 344,000 [38]. Ectopia lentis, which
is often associated with classical homocystinuria [39, 40],
occurs in 85% of classical homocystinuria [39, 41, 42]. In a
report on 294 patients with mucopolysaccharidoses, 27 eyes
of 14 patients had glaucoma and the prevalence of glaucoma
was reported from 2.1% to 12.5% [43].
2.5. Mitotic Disorders. Thegroup ofmitotic disorders leading
to childhood glaucoma includes juvenile xanthogranuloma,
the prevalence of which is unknown. It occurs in the pediatric
age and 10% of patients present ocular anomalies with
occasional glaucoma [44].
2.6. Other Congenital Conditions. The prevalence of trisomy
13 or Patau’s syndrome is 1/6500 where glaucoma has been
reported among the ocular complications [45].
In a study of 62 cases of persistent hyperplastic primary
vitreous, Haddad et al. reported 26 patients where other
ocular abnormalities such as leukocoria, microphthalmia,
cataract, retinal detachment, glaucoma, and phthisis bulbi
were observed [46].
Five to twenty percent of pediatric blindness is attribu-
table to congenital cataract, which occurs in 3-4 per 10 000
births [47]. Although new surgical techniques have been
introduced, the incidence of secondary glaucoma following
cataract operations in the pediatric age is still high, varying
from 6% to 26% [48]. If the surgical procedure is performed
before the 9th month of life, the incidence of glaucoma may
rise to 50% [48, 49]. Rubinstein-Taybi syndrome as well
as congenital rubella appears among congenital disorders
associated with glaucoma. Rubinstein-Taybi syndrome has an
incidence of 1 in 100 000 newborns [50]. van Genderen et
al. reviewed 207 patients with Rubinstein-Taybi syndrome,
and 117 had ocular disorders. Congenital glaucoma was
described in 31 cases [51]. Epidemiological assessments of
ocular disease in large populations of congenital rubella are
few. In France just 21 cases of rubella during pregnancy were
reported in 2001 and only one child presented congenital
rubella syndrome at birth [52]. Various ocular disorders such
as retinopathy, cataract, and glaucoma may occur in this
condition [53]. In a prospective study byO’Neill in 34 patients
with rubella, glaucoma was observed in 29% (11 eyes) and
was in the context of microphthalmic eyes in 4 patients [54].
Table 2 is a summary of the epidemiology and percentage
of glaucoma in rare diseases leading to secondary childhood
glaucoma.
2.7. Rare Diseases. Cases reports of congenital glaucoma have
been reported in the context of rare systemic syndromes
such as otopalatodigital syndrome type II (OPD II) [55],
complete androgen insensitivity [56], pseudotrisomy 13 [57],
Brachmann-de Lange syndrome [58], autosomal recessive
acrofrontofacionasal dysostosis [59], caudal regression syn-
drome [60], and Wolf-Hirschhorn syndrome [61] (Table 3).
3. Genetics and Pathophysiology
3.1. Primary Congenital Glaucoma. While most cases of
primary congenital glaucoma are sporadic, 10% to 40% are
familial and are often associated with consanguinity [62].
Familial forms have autosomal recessive inheritance with
variable expression in 40 to 100% of cases [63]. However,
the autosomal recessive inheritance modality has been chal-
lenged due to the discrepancy between gender distribution,
transmission of childhood glaucoma to offspring, and lower
predicted afflicted siblings in familial cases [63]. Linkage
studies confirm the heterogeneity of primary congenital
glaucoma, so these discrepancies can be explained [63, 64].
Primary congenital glaucoma has been associated with
3 chromosomal loci: chromosomes 2p21 (GLC3A), 1p36
(GLC3B), and 14q24 (GLC3C) [62, 63, 65, 66].
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Table 2: Epidemiology and percentage of glaucoma in rare diseases leading to childhood glaucoma.
Primary congenital glaucoma 1 in 10,000 to 68,000
Secondary childhood glaucoma
Disease Prevalence of disease Percentage of glaucoma in disease
Mesodermal
dysgeneses of neural
crest
Iridocorneal trabeculodysgenesis
(i) Aniridia From 1/40,000 to1/100,000 6–75% [16–18, 24]
(ii) Axenfeld-Rieger’s anomaly (syndrome if
systemic associations) 1–9/1000000 50% [13]
(iii) Peter’s anomaly (syndrome if systemic
associations) 1/1000000 Not available
(iv) Marfan’s syndrome 1/5000 2% [20]
(v) Weill-Marchesani syndrome 1/100000 80% [21]
Von Recklinghausen’s syndrome 1/3000 1% [17, 24], 23% of patients withipsilateral craniofacial anomalies [25]
Phakomatoses
Encephalotrigeminal angiomatosis (Sturge-Weber
syndrome and variants such as Klippel-Trenaunay
syndrome)
1/50000
50–70% [27] (100% incidence in cases
associated with oculodermal
melanocytosis [32])
Oculodermal melanocytosis 14/100000 to34/100000 10% [29, 32]
Lowe’s syndrome 1/500000 71% [34]
Metabolic disorders Homocystinuria 1/344000 85% of cases with ectopia lentis[38, 39, 41, 42]
Mucopolysaccharidoses 1/25000 2.1% to 12.5% [43, 95]
Mitotic disorders Juvenile xanthogranuloma Unknown
10% of patients present ocular
anomalies with occasional glaucoma
[44]
Other congenital
disorders
Trisomy 13 (Patau’s syndrome) 1/6500 Not available
Persistent hyperplastic primary vitreous Unknown
31% of patients present ocular
abnormalities with occasional
glaucoma [46]
Congenital cataract 1–6/10000 6–26% following cataract surgery [48]
Rubinstein-Taybi syndrome Unknown 15% [51]
Congenital rubella Unknown 29% [54]
The mutation of the CYP1B1 gene is involved in 87% of
familial and 27% of sporadic cases of congenital glaucoma
[63]. Currently 147 mutations of this gene have been found,
including point missense, nonsense, frameshift, terminator
mutations, deletion, and insertion with significant hetero-
geneity [67, 68]. CYP1B1 is a drug-metabolizing enzyme of
the cytochrome p450 gene family. It is expressed in a large
spectrum of tissues including the iris, trabecular meshwork,
ciliary body, and anterior uveal tract of the eye [69]. Ocular
development is associated with the signalling molecule,
metabolized by the gene product, but the procedure still
needs clarification [68]. Primary congenital glaucoma is not
related to juvenile or adult onset open angle glaucoma linked
to the MYOC (TIGR) gene on chromosome 1q25 at locus
GLCIA [70], but in some cases a mutation in the CYP1B1 has
been found [71].
Alteration of the trabecularmeshwork leading to a reduc-
tion of aqueous outflow results in childhood glaucoma. It
may be a consequence of developmental defects or trabecular
structure immaturity [72, 73]. There is no documentation of
imperforate Barkan’s membrane over the anterior chamber
angle, although the trabecular meshwork anomaly was ini-
tially described as a “clothed membrane with a shagreened
surface” [74–76]. The histopathology of childhood glaucoma
is characterized by five different features. One such aspect is
an anterior insertion of the iris and ciliary body; thus, the
trabecular meshwork is inconsistently exposed to aqueous
deflux [76]. The overlap between the ciliary body in its
anterior section and the trabecular meshwork in its posterior
part leads to poor development of the angle recess. The
ciliary muscle, with its longitudinal fibers, passes the internal
tip of a poorly developed scleral spur; thus, it obtrudes
in the corneoscleral meshwork [77]. The second feature
consists in taut and thickened trabecular beams in the
meshwork [62]. A third characteristic is a less porous and
thicker juxtacanalicularmeshwork [76, 78, 79] possibly due to
scarce differentiation [73]. Fewer vacuoles in Schlemm’s canal
endothelium have been described in eyes affected by congen-
ital glaucoma; this may be either an artefact or a consequence
of the decrease of aqueous flow [76, 78, 79]. Finally, agenesis
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Table 3: Epidemiology and glaucoma in rare diseases that do not
usually include congenital glaucoma among their manifestations.
Secondary glaucoma
Disease Prevalence ofdisease
Percentage of
glaucoma in the
disease
Rare diseases
Otopalatodigital
syndrome type II Unknown One case [55]
Complete androgen
insensitivity 1–9/1000000 One case [56]
Pseudotrisomy 13 Unknown One case [57]
Brachmann-de Lange
syndrome 1–9/100000 One case [58]
Acrofrontofacionasal
dysostosis with
genitourinary
abnormalities
Unknown One case [59]
Wolf-Hirschhorn
syndrome 1–9/1000000 One case [61]
of Schlemm’s canal has been described; it occurs rarely and
probably indicates more severe maldevelopment [73, 80].
Similarity of the angle histopathology between some cases
of secondary childhood glaucoma and primary congenital
glaucoma suggests that a common pathophysiogeneticmech-
anism related to angle development may exist.
3.2. Mesodermal Dysgeneses of the Neural Crest. Secondary
childhood glaucoma in conjunction with ocular or systemic
disorders can be gathered in different subgroups according
to their etiology. It can be associated with mesodermal
dysgenesis of the neural crest. Several syndromes result
from an abnormal development of neuroectodermal cells
[13]. In the eye, anterior chamber development follows the
migration of neural crest cells forming keratocytes, corneal
endothelium, iris stroma,melanocytes, trabecularmeshwork,
and juxtacanalicular tissue [13]. The gamma of anterior
segment dysgeneses, or Axenfeld-Rieger syndrome, is not
linked to genetic factors in congenital glaucoma.Mutations in
the PITX2 and FOXC1 transcription factor genes account for
anterior segment dysgeneses, which are autosomal dominant
disorders [81, 82]. A developmental arrest or an abnormal
migration of neural crest cells, occurring late in gestation,
may lead to chamber malformation resulting in Axenfeld-
Rieger anomaly, Peter’s anomaly, aniridia or iris hypoplasia,
sclerocornea, megalocornea, and congenital glaucoma [13,
83]. These anomalies together with the Marfan and Weil-
Marchesani syndromes are linked to glaucoma because of an
abnormal anterior chamber angle that effects the drainage of
aqueous humour [13].
3.3. Phakomatoses. Several cases of secondary congeni-
tal glaucoma have been reported in association with the
phakomatoses and hamartomas. Neurofibromatosis type 1,
encephalotrigeminal angiomatosis (Sturge-Weber syndrome
and variants such as Klippel-Trenaunay syndrome), retinal
and cerebellar angiomatosis, and oculodermal melanocytosis
are included among these multisystem disorders [3, 84].
Glaucoma onset is seldom encountered in neurofibromatosis
type 1 and the pathophysiological mechanisms reported
are infiltration of the anterior chamber by neurofibromas,
Lisch nodules in the chamber angle leading to secondary
angle closure, increase in thickness of the ciliary body and
choroid, and developmental angle abnormalities [85–88].
Secondary childhood glaucoma is frequently associated with
the Sturge-Weber and Klippel-Trenaunay syndromes and
with phakomatosis pigmentovascularis which have the facial
naevus flammeus in common.This is due to anterior chamber
malformation or raised episcleral venous pressure [30, 89–
91]. In phakomatosis pigmentovascularis glaucoma can also
be due to an increase in melanocytes which clog the angle.
Glaucoma is not strictly part of the manifestations of the
other phakomatoses, namely, Von Hippel-Lindau disease,
which is characterized by retinal angiomatosis and sclerosis
tuberous complex characterized by retinal hamartomas. In
these diseases glaucoma has only been reported among the
complications of retinal detachment [92].
3.4. Metabolic Disorders. Congenital glaucoma may secon-
darily occur in the context of metabolic disorders such as
mucopolysaccharidoses, Lowe’s syndrome, and hyperhomo-
cysteinemia [3]. In these diseases the incidence of secondary
glaucoma is attributed to both an anomalous structure of
the anterior chamber and engorgement of the trabecular
meshwork by extracellular material [3, 29, 84, 93, 94].
The mucopolysaccharidoses are inherited conditions with
intra- and extracellular accumulation of glycosaminoglycans
(GAG). All subtypes show ocular disorders among which are
opacification of the cornea, retinal pathology, and secondary
glaucoma [95]. Narrowing of the angle and obstruction of
trabecular outflow are secondary to an accumulation of GAG
within trabecular cells. [95].
Another condition in this group of metabolic disorders
is Lowe’s syndrome (oculocerebrorenal syndrome), a rare X-
linked, recessively transmitted disease [28] which is charac-
terized by amutation of phosphatidylinositol 4,5 biphosphate
5-phosphatase, resulting in intracellular accumulation of its
PIP2 substrate leading to systemic anomalies involving the
kidneys, central nervous system, and the eyes [96]. Classical
homocystinuria follows an autosomal recessive mode of
inheritance and is a disorder of methionine metabolism
[97] due to deficiency of cystathionine b-synthase (CbS)
[30–32]. Ectopia lentis represents the most common clinical
anomaly leading to diagnosis in most cases [34, 35]. Anterior
dislocation of the lens sometimes leads to acute pupillary
block with a resulting secondary glaucoma [34].
3.5.Mitotic Disorders. Mitotic disorders such as juvenile xan-
thogranuloma may present secondary congenital glaucoma
as their ocular manifestation [84]. Juvenile xanthogranuloma
is due to histiocytic abnormalities that rarely occur in the
pediatric age [98, 99].This disease can damage various ocular
structures, but the iris is most frequently affected [100]. The
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onset of secondary glaucoma is frequently related to the
presence of iris nodules that, due to their vascular nature,may
bleed causing hyphema [101].
3.6. Other Congenital Conditions. Secondary childhood glau-
coma can also be associated with other disorders such as
persistent hyperplastic primary vitreous, congenital cataract,
Patau’s syndrome, Rubinstein-Taybi syndrome, or congenital
rubella [84, 102, 103]. Secondary childhood glaucoma is
often associated with congenital cataract and it may occur as
postoperative complication of pediatric cataract surgery [48].
Different ocular anomalies are associated with Rubinstein-
Taybi syndrome, which results from microdeletions at chro-
mosome 16p13.3 or frommutations in the gene for the CREB
binding protein (CBP), located at 16p13.3 [104, 105].
3.7. Acquired Conditions. Uveitis and steroid induced glau-
coma are among the major acquired conditions associated
with childhood glaucoma. Trauma induced glaucoma can
be caused by hyphema, angle recession, and ectopia lentis.
Ocular or orbital, benign or malignant, tumors and retinopa-
thy of prematurity can also be a cause. Retinopathies and
some drugs can also cause secondary glaucoma and the
pathophysiogenetic mechanism is specific to each condition
[106–108].
3.8. RareDiseases. There are some rare diseases, which donot
normally present glaucoma in their manifestation.
Kondoh et al. published a case of bilateral glaucoma in
a male child presenting otopalatodigital syndrome type II
(OPD II) related to a mutation of the gene for filamin A
(FLNA). Performing a sequence analysis of the FLNA gene,
a missense C to T mutation at position 588, resulting in
an Arg196Trp change in the filamin A protein, was found
[55]. FLNA gene encodes an actin-binding protein and
mutations of the FLNA gene have been found in OPD II,
Melnick-Needles syndrome, or frontometaphyseal dysplasia.
The association between OPD II, congenital heart defects,
and ocular disorder, as presented by Kondoh et al., has not
been previously reported. Therefore, additional factors are
probably involved in the pathogeneticmechanism behind the
OPD-group alterations [55].
Gad et al. reported an association of complete androgen
insensitivity with hypertrophic pyloric stenosis and congeni-
tal glaucoma in an Egyptian newborn. Performing a sequence
of the five exons of the 5a-reductase type 2 gene, no evidence
of mutation was obtained while a C to T mutation, which
resulted in substitution of the phenylalanine residue by a
leucine at position 804, was identified in exon 6. The father’s
family had a history of glaucoma, ruling out the causative
effect of the receptor gene in the pathogenesis of glaucoma
and exon 6 of the androgen receptor gene of the mother
was normal; therefore, the mutation was considered de novo.
It is possible that defective androgen action determined
the congenital glaucoma. Moreover, it is interesting to note
that CYP1B1 gene, which is the most common early-onset
glaucoma gene, is related to steroids. The CYP1B1 gene lies
next to the SRD5A2 gene on 2p21 and both the androgen
receptor and SRD5A2 genes are expressed in eye structures.
However, the consequences of defective signalling pathways
on the structure and function of ocular tissues and the
correlated gene are still unknown [56].
Sandal et al. reported the only case of congenital glau-
coma in a female infant affected by pseudotrisomy 13.
Detailed genetic examination, conventional karyotype, and
microarray studies are necessary to assess anomalies that are
not usually related to this syndrome [57].
Barry Lee et al. first reported a case of buphthalmos
and childhood glaucoma associated with Brachmann-de
Lange syndrome. Chromosome 3q16 is probably related to
Brachmann-de Lange syndrome, while some forms of herita-
ble childhood glaucoma have been mapped to chromosomes
1 and 2. Further genetic studies could be useful to assess a
correlation between these disorders [58].
Chaabouni et al. reported the first case of congenital
glaucoma in a patient who suffered from acrofrontofacionasal
dysostosis with genitourinary abnormalities [59]. As far as we
know, this is one of just three case reports in this condition,
which has autosomic recessive transmission. The paucity of
cases precludes our understanding of the ophthalmological
anomalies. Guirgis et al. first reported a case of childhood
glaucoma associated with caudal regression syndrome in a
10-week-old infant. The child also had punctal atresia and
significant myopia. Embryonic defect of caudal mesodermal
development seems to be the cause of caudal regression
syndrome [109]. However, goniodysgenesis, caused by neural
crest alterations, probably led to childhood glaucoma. A
faulty development of surface ectoderm is related to punctual
atresia. The embryopathic nature of both caudal regression
syndrome and childhood glaucoma, as well as their low
incidence, implies that theremight be a common cause rather
than a coincidence. Furthermore, concomitant punctual
atresia validates the notion of embryopathic linkage [110].
Dickmann et al. tried to analyze the relationship between
Wolf-Hirschhorn syndrome and ocular defects, specifically
to correlate ocular findings with the extension of deletion
on chromosome 4, so they investigated a population of 10
patients affected by Wolf-Hirschhorn syndrome [61]. This
condition is a genetic disorder that occurs as a consequence of
partial deletion of the short arm of chromosome 4; the prox-
imal breakpoint occurs between 4p15.1 and 4p16.3, and the
smallest and largest deletion sizes recorded were 2.6Mb and
20Mb, respectively [61, 111, 112]. Ocular anomalies appeared
in all patients, but just one patient was affected by childhood
glaucoma. Comparing genotype with ocular findings, severe
ocular abnormalities were associated with large 4p deletions
while mild ocular disorders were independent of the deletion
size [61]. The only case of childhood glaucoma was observed
at birth; it appeared with concomitant corneal clouding, iris
coloboma, and cataract. It was associated with a large 4p
deletion [61, 113].
4. Management
The signs and symptoms of childhood glaucoma are closely
linked to the age of onset and the gravity of the disease;
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however, some children are asymptomatic. Corneal alter-
ations can be edema, Descemet’s membrane breaks, and
opacification.This leads to the typical manifestations of pho-
tophobia, epiphora, and consequent blepharospasm. In some
cases a misinterpretation of these symptoms delays diagnosis
[62]. Improved instrumental technology with optical coher-
ence tomography and ultrabiomicroscopy can provide details
on the anterior chamber and ciliary body which is helpful
towards diagnosis [114, 115]. The management of childhood
glaucoma is also facilitated by new instrumentation to mea-
sure intraocular pressure and visual field defects [116–119].
Any type of glaucoma leads to irreversible vision loss
in the long term; therefore, the goal of both medical and
surgical management is to prevent visual deterioration [62].
Treatment should be carefully tailored, aiming to control
intraocular pressure in the course of time. Surgical pro-
cedures represent the mainstay of therapy for childhood
glaucoma. Although medical therapy alone is rarely effective,
it plays an important role as adjunctive treatment to surgery;
moreover, it can also be used temporarily before surgery to
clear the cornea [62]. Ophthalmologists who use medication
should be aware of different risk and benefit profiles in
infants and children compared with adults. Allergic reactions
and ocular surface toxicity may complicate repeated topical
treatment initiated at an early age in childhood [62].
4.1. Medical Treatment. Beta-blockers are usually well toler-
ated and severe systemic complications are rare in pediatric
patients treated with timolol, but bradycardia and bron-
chospasm can occur especially with the concentration of
0.5%. Cautious initial treatment with low concentrations
of timolol is wise. Punctal occlusion after topical timolol
determines a decrement of beta-blocker plasma levels, so
the use of punctual occlusion after every drop application is
advised [62].
Oral carbonic anhydrase inhibitors represent the most
efficacious drugs in the reduction of intraocular pressure
in childhood glaucoma. Nevertheless it is important to be
aware that these can cause decreased appetite and hyperpnea
from renal acidosis, dehydration, chronic fatigue, and failure
to grow, so prolonged use should be avoided [62]. Topical
carbonic anhydrase inhibitors such as dorzolamide and brin-
zolamide represent a valid alternative to oral administration
with less risk of systemic side effects.They reduce intraocular
pressure by 25% [120, 121]. Carbonic anhydrase inhibitors and
beta-blockers are both suppressors of aqueous production
but are used in conjunction in order to yield additive
benefit [122]. Brimonidine is a selective alpha-agonist, which
reduces intraocular pressure increasing uveoscleral outflow
and decreasing aqueous production [123]. Since brimonidine
crosses the blood brain barrier, it can lead to nervous systemic
toxicity [124]. Brimonidine topical therapy has also been
reported to induce bradycardia, hypotension, hypotonia,
hypothermia, apnea, and unresponsiveness in children [125–
128].
Prostaglandin analogues such as bimatoprost, travo-
prost, and latanoprost are not effective in pediatric patients.
Although in some cases of children affected by primary
juvenile glaucoma and glaucoma related to Sturge-Weber
syndrome a significant intraocular pressure reduction was
found [129, 130], further research is necessary in order to
assess the performance of prostaglandins in the treatment of
childhood glaucoma.
Miotics such as pilocarpine are not effective for childhood
glaucoma. In older children, symptoms of spasmof the ciliary
muscle and blurring of vision from induced myopia occur.
They can be used for aphakic glaucoma and are adoperated
before goniosurgery [62]. Most often childhood glaucoma is
better managed surgically rather than medically [62].
4.2. Surgical Treatment. Surgical treatment can be separated
into procedures that improve aqueous outflow through the
drainage channels (goniosurgery such as goniotomy and tra-
beculotomy), treatments that by destroying the ciliary body
reduce aqueous humor production (cyclodestruction), or
surgical procedures that drain aqueous through an alternative
way (trabeculectomy, glaucoma drainage devices) [131].
While for primary congenital glaucoma goniotomy rep-
resents the procedure of choice, this indication is less certain
for other forms of childhood glaucoma [62]. An alternative
surgical treatment is trabeculotomy [62]; it appears as a more
appropriate choice especially when a cloudy cornea prevents
a comfortable visualization of the angle [62]. Filtering surgery
may be indicated if goniosurgery procedures are unsuccessful
[3]. Trabeculectomy is indicated if an unacceptable elevation
of intraocular pressure persists after an adequate number of
angle incision procedures [62]. Implant surgery represents
a valid alternative for patients with conditions proven to be
refractory to goniosurgery or filtering surgery, who are poor
candidates to these procedures, or for whom these treatments
have been revealed unsuccessful [62]. Long tube drainage
device surgery is needed in severe cases of primary congenital
glaucoma and, sometimes, in secondary glaucomas [3].
Cyclodestructive procedures can be defined as an inter-
mediate or an additional procedure, useful when primary
trabecular surgery has failed [3]. Cyclocryotherapy or both
transscleral and endoscopic diode laser cyclophotocoagu-
lation are used for the ablation of ciliary epithelium. The
surgeon must consider the anatomic improvement, the long-
term visual benefit, and the patient’s expectations for the
affected eye when making the choice for management strate-
gies [62].
5. Conclusions
There is a wide array of systemic diseases associated with
childhood glaucoma. Some conditions like dysgenesis of the
anterior chamber associated with neural crest disorders and
the phakomatoses are better known. However, there are rare
diseases which are occasionally associated with glaucoma.
Since the examination of pediatric patients is not always
straightforward, ophthalmologists should be updated on the
available literature and should bewell aware of the conditions,
which may lead to visual deterioration due to glaucoma.
Treatment should be carefully tailored, in order to control
intraocular pressure in the long term. Surgical treatment is
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the mainstay of management and medical therapy has an
adjunctive role. Furthermore, medication should be carefully
monitored due to different risk and benefit profiles in infants
and children compared with adults. A multidisciplinary
approach to pediatric patients with rare multisystem diseases
is highly advisable in both the diagnosis and management of
the conditions.
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